Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Esomeprazole vs Nexium in Healthy Thai Volunteers
NCT06233149Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of esomeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Bio-innova. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration at 24 hours, Maximal measured plasma concentration at 24 hours and 1 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06233149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233149.